Moderna amends credit agreement, cuts loan margins and extends maturity
The company lowered interest rate margins on its term loans by 0.75 percentage points and pushed the maturity date out one year to November 2031.
SEC filing
6 stories
The company lowered interest rate margins on its term loans by 0.75 percentage points and pushed the maturity date out one year to November 2031.
SEC filing
Klinger will remain through March 2027 under a retirement deal that includes payments tied to the outcome of ongoing litigation.
SEC filing
Arbutus reported a $337.5 million cash position for the third quarter of 2026 and said the FDA cleared AB-101 for further U.S. development while it widened LNP patent litigation against Pfizer and BioNTech.
SEC filing
Data presented at SITC 2026 found neoantigen-specific T cells detectable directly ex vivo and a strong statistical link between AI-Immunology predictions and actual T-cell responses.
SEC filing, Drugs@FDA (9)
Moderna named Juan Andres Chief Operating Officer effective October 5, 2026, as the company said it prepares for a possible launch of its cancer therapy intismeran autogene and expands its vaccine lineup.
SEC filing